Data gathered: November 23
AI Stock Analysis - Organon & Co. (OGN)
Analysis generated October 7, 2024. Powered by Chat GPT.
Organon Co. is a global healthcare company focused on improving the health of women throughout their lives. The company’s portfolio includes treatments for reproductive health, heart disease, dermatology, allergies, and asthma. They spun off from Merck & Co., Inc. in 2021, establishing a unique focus on women’s health and other critical health segments. The firm is relatively new as an independent entity, and their development strategy revolves around organic growth, strategic partnerships, and acquisitions.
Stock Alerts - Organon & Co. (OGN)
 |
Organon & Co. | November 5 Price is down by -5.5% in the last 24h. |
|
Organon & Co. | November 5 Employee Rating is down by 2.5% over the last month. |
|
Organon & Co. | November 4 Price is down by -5.1% in the last 24h. |
|
Organon & Co. | October 30 Job postings are up by 25% in the last couple of days. |
Alternative Data for Organon & Co.
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 276 | Sign up | Sign up | Sign up |
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 259,000 | Sign up | Sign up | Sign up |
| Employee Rating | 80 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| Patents | 5 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | 21 | Sign up | Sign up | Sign up |
| Facebook Followers | 2,014 | Sign up | Sign up | Sign up |
| Instagram Followers | 7,495 | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 2 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 1,160 | Sign up | Sign up | Sign up |
| Twitter Followers | 733 | Sign up | Sign up | Sign up |
| Twitter Mentions | 103 | Sign up | Sign up | Sign up |
| Youtube Subscribers | 388 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | 66 | Sign up | Sign up | Sign up |
| Lobbying Cost | $123,000 | Sign up | Sign up | Sign up |
| Business Outlook | 56 | Sign up | Sign up | Sign up |
| Linkedin Employees | 7,053 | Sign up | Sign up | Sign up |
About Organon & Co.
Organon & Co is a science-based global pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. Its two operating segments are the Organon Products segment and the Merck Retained Products segment. It operates in the United States, China, Japan, Korea, and countries in Europe.
| Price | $15.28 |
| Target Price | Sign up |
| Volume | 2,550,000 |
| Market Cap | $3.83B |
| Year Range | $14.59 - $22.62 |
| Dividend Yield | 7.52% |
| PE Ratio | 2.95 |
| Analyst Rating | 38% buy |
| Industry | Drug Manufacturers |
In the news
 |
Organon & Co. (NYSE:OGN) Shares Acquired by Crossmark Global Holdings Inc.November 18 - ETF Daily News |
|
CWA Asset Management Group LLC Makes New $355,000 Investment in Organon & Co. (NYSE:OGN)November 13 - ETF Daily News |
|
M&G Plc Has $3.88 Million Stake in Organon & Co. (NYSE:OGN)November 9 - ETF Daily News |
|
Van ECK Associates Corp Purchases 67,451 Shares of Organon & Co. (NYSE:OGN)November 9 - ETF Daily News |
 |
Organon's (NYSE:OGN) Earnings Are Weaker Than They SeemNovember 7 - Yahoo |
|
Earnings Update: Organon & Co. (NYSE:OGN) Just Reported Its Third-Quarter Results And Analysts Are Updating Their ForecastsNovember 5 - Yahoo |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 1.58B | 659M | 923M | 359M | 390M | 0.870 |
| Q2 '24 | 1.61B | 668M | 939M | 195M | 452M | 1.120 |
| Q1 '24 | 1.62B | 665M | 957M | 201M | 479M | 1.220 |
| Q4 '23 | 1.6B | 1.33B | 272M | 546M | 370M | 0.880 |
| Q3 '23 | 1.52B | 612M | 907M | 58M | 228M | 0.870 |
Insider Transactions View All
| Weaver Kirke filed to buy 15,181 shares at $18.4. February 23 '24 |
Similar companies
| Company | Price | AI Score | |
|---|---|---|---|
 |
Johnson & JohnsonJNJ |
$155.17 0% | 51 |
 |
Eli Lilly and CompanyLLY |
$748.01 0% | 64 |
 |
PfizerPFE |
$25.65 0% | 47 |
 |
AstrazenecaAZN |
$65.63 0% | 71 |
 |
AbbVieABBV |
$176.95 0% | 59 |
Congress Trading View All
| Politician | Filing Date | Type | Size |
|---|---|---|---|
| Rohit Khanna Democrat |
Nov 8, 23 | Buy | $1K - $15K |
| Rohit Khanna Democrat |
Aug 7, 23 | Sell | $1K - $15K |
| Rohit Khanna Democrat |
Jul 11, 23 | Buy | $1K - $15K |
Read more about Organon & Co. (OGN) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, facebook engagement, facebook followers, instagram followers, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, youtube subscribers, news mentions, customer reviews, lobbying cost, business outlook & linkedin employees.
What is the Market Cap of Organon & Co.?
The Market Cap of Organon & Co. is $3.83B.
What is Organon & Co.'s PE Ratio?
As of today, Organon & Co.'s PE (Price to Earnings) ratio is 2.95.
What is the current stock price of Organon & Co.?
Currently, the price of one share of Organon & Co. stock is $15.28.
How can I analyze the OGN stock price chart for investment decisions?
The OGN stock price chart above provides a comprehensive visual representation of Organon & Co.'s stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Organon & Co. shares. Our platform offers an up-to-date OGN stock price chart, along with technical data analysis and alternative data insights.
Does OGN offer dividends to its shareholders?
Yes, Organon & Co. (OGN) offers dividends to its shareholders, with a dividend yield of 7.52%. This dividend yield represents Organon & Co.'s commitment to providing value to its shareholders through both potential capital appreciation and steady income. Investors considering Organon & Co. in their portfolio should factor in this dividend policy alongside the company's growth prospects and market position.
What are some of the similar stocks of Organon & Co.?
Some of the similar stocks of Organon & Co. are Johnson & Johnson, Eli Lilly and Company, Pfizer, Astrazeneca, and AbbVie.
.